Ramaphosa urged to press for wider access to Gilead’s HIV shot in SA
Civil society groups urged President Cyril Ramaphosa to push Gilead to expand access to lenacapavir, a twice-yearly HIV prevention shot, ahead of its launch in Secunda, Mpumalanga. They said South Africa will receive under 975,000 doses in two years (38,000 arrived by April) versus HE2RO modelling of ~2 million annual doses needed. They criticized delayed rollout tied to Sahpra testing and limited generic licensing.
Potential reputational/regulatory pressure on Gilead tied to SA rollout delays and calls to expand supply and licensing terms.
Article centers on civil society urging Gilead to speed lenacapavir access after SA received fewer than 975,000 doses and rollout delays.
Limited direct near-term price signal for Gilead; any impact is likely indirect via sentiment/regulatory overhang rather than a discrete earnings catalyst.
Background
Lenacapavir is a twice-yearly HIV prevention shot; South Africa approved it first in Africa but has lagged in rollout due to regulatory and supply-allocation issues.
Why it matters
Civil society groups criticize the rollout plan as too small/slow and fault Gilead for not seeking exemptions to SAHPRA testing requirements and for licensing limits tied to API capacity. SA health officials plan a phased launch across three provinces with prioritization of high-risk groups.
Market relevance
The piece is primarily a policy/access story; for markets, it mainly affects sentiment around Gilead’s access commitments and potential regulatory/licensing scrutiny rather than announcing a financial or clinical catalyst.
Market effects
Could increase scrutiny of HIV prevention drug supply commitments, regulatory testing timelines, and voluntary licensing mechanics for next-gen antivirals.
South Africa’s rollout constraints (post-import testing delays; low near-term targets) may slow expected public-health impact despite approvals.
Read-across risk for other high-burden countries: pressure to broaden access, accelerate supply, and adjust licensing/API constraints.
Alternative perspectives
Regulatory testing delays may be procedural rather than supply-constrained; rollout sequencing could still ramp after initial post-importation compliance is met.
The article emphasizes dose volumes and targets but does not quantify Gilead’s total committed supply, manufacturing capacity, or whether SA’s testing backlog is the binding constraint.
Key entities
- pharmaceutical manufacturerGilead
Manufacturer of lenacapavir; criticized for supply allocation, regulatory approach, and licensing/API constraints.
- regulatorSouth African Health Products Regulatory Authority (Sahpra)
Imposed post-importation testing requirements that delayed rollout after doses arrived.
- civil society organizationTreatment Action Campaign
Part of the coalition urging Ramaphosa to press for wider access to lenacapavir.
- licensing intermediaryMedicines Patent Pool
Awarded voluntary licenses to manufacturers, with conditions related to API capacity that Gilead later softened.
